<DOC>
	<DOCNO>NCT01349790</DOCNO>
	<brief_summary>NewGam newly develop human normal immunoglobulin solution intravenous administration ( IGIV ) . This study evaluate safety efficacy NewGam 10 % patient primary immune thrombocytopenia .</brief_summary>
	<brief_title>Efficacy Safety Immunoglobulin Intravenous ( Human ) 10 % ( NewGam ) Primary Immune Thrombocytopenia</brief_title>
	<detailed_description>The primary objective study assess efficacy NewGam correct platelet count . The secondary objective study evaluate safety NewGam . Safety assess monitor vital sign , physical examination , evaluation adverse event ( AE ) laboratory parameter , viral safety testing .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Age ≥ 18 ≤ 80 year . 2 . Confirmed diagnosis chronic primary immune thrombocytopenia ( ITP ) threshold platelet count &lt; 100x10^9/L ) least 12 month duration . 3 . Platelet count 20x10^9/L without bleed manifestation . 4 . Freely give write informed consent patient . 5 . Women childbearing potential must negative result pregnancy test ( human chorionic gonadotropine [ HCG ] base assay ) need practice contraception use method proven reliability duration study . 1 . Thrombocytopenia secondary disease ( acquire immunodeficiency syndrome [ AIDS ] systemic lupus erythematosus [ SLE ] ) drugrelated thrombocytopenia . 2 . Administration intravenous immunoglobulin ( IGIV ) , antiD immunoglobulin thrombopoetin receptor agonist , platelet enhance drug ( include immunosuppressive immunomodulatory drug ) within 3 week enrollment , except : Longterm corticosteroid therapy dose stable precede 3 week dosage change plan study Day 22 . Longterm azathioprine , cyclophosphamide , attenuate androgen therapy dose stable precede 3 month dosage change plan study Day 22 . 3 . Unresponsive previous treatment IGIV antiD immunoglobulin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ITP</keyword>
	<keyword>Primary immune thrombocytopenia</keyword>
</DOC>